Key result
Complete resection remains the best treatment for primary cardiac spindle cell sarcoma with 6-month average survival.
Case Report
Spindle cell sarcoma is an extremely rare and lethal primary cardiac tumor where complete resection remains the best available treatment despite a poor prognosis.
Alerts clinicians to this rare entity in cardiac mass differentials; case-level data leave optimal adjunctive strategies open.
Primary cardiac tumors are extremely rare. Incidence is approximately 0.017% of all primary tumors. Spindle cell sarcoma is the rarest, with only four cases reported and there are no guidelines for treating this condition. Cardiac sarcomas have symptoms by different mechanisms including obstruction, local invasion, and embolisms and in some cases the first manifestation could be a sudden cardiac death. Diagnosis is made with imaging techniques such as echocardiogram, cardiac computed tomography (CT), and magnetic resonance imaging (MRI) and confirmed with tissue biopsy. Patients with malignant tumors have a poor prognosis with an average mean survival of 6 months. Complete resection of the tumor remains the best treatment available. Spindle cell sarcoma may present with few symptoms and may remain silent until an advanced stage, thus limiting the few therapeutic options available. J Med Cases. 2016;7(11):498-501 doi: http://dx.doi.org/10.14740/jmc2663w
No takes yet. Share an insight, caveat, or question.
Caliz et al. (2016) conducted a case report in Primary cardiac spindle cell sarcoma. Primary cardiac spindle cell sarcoma is an extremely rare and lethal tumor with an average survival of 6 months, for which complete resection remains the best available treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: